Boehringer Ingelheim Pharmaceuticals Inc.

Aug 29, 2017

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo(TM) (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases

Aug 27, 2017

RE-DUAL PCI(TM) Results Offer Favorable New Safety Data on Pradaxa®

Jul 31, 2017

Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

Jun 05, 2017

Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Jun 01, 2017

Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®